InvestorsHub Logo
Post# of 252218
Next 10
Followers 833
Posts 119848
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 197801

Monday, 03/09/2020 10:02:42 AM

Monday, March 09, 2020 10:02:42 AM

Post# of 252218
BMY/ABBV—Empliciti failed to show statsig-better PFS when added to Revlimid/dexamethasone in first-line MM in phase-3 ELOQUENT-1 study:

https://finance.yahoo.com/news/bristol-myers-squibb-reports-primary-105900628.html

PFS was the primary endpoint. HR and other data have not yet been disclosed.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.